CD81-AS1

Across TCGA pan-cancer cohorts, CD81-AS1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CD81-AS1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CD81-AS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD81-AS1 expression acts as an unfavorable survival marker.

OV, ESCA, and SKCM are the cancer types where CD81-AS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.023	0.844	<.001	36	view →
ESCA	OS	Median	All	0.141	0.680	.004	3	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CD81-AS1–OV (OS)

Open the OV breakdown →